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Abstract
Background—Rhinoviruses (RVs) are ubiquitous respiratory pathogens that often cause mild or 
subclinical infections. Molecular detection of RVs from the upper respiratory tract can be 
prolonged, complicating etiologic association in persons with severe lower respiratory tract 
infections. Little is known about RV viremia and its value as a diagnostic indicator in persons 
hospitalized with community-acquired pneumonia (CAP).
Correspondence: X. Lu, MS, Division of Viral Diseases, Centers for Disease Control and Prevention, 1600 Clifton Rd, NE, MS G04, 
Atlanta, GA 30329 (xal9@cdc.gov).†Deceased.
Presented in part: Sixth International Meeting on Emerging Diseases and Surveillance, Vienna, Austria, November 2016. Poster 
number: 20.016.
Disclaimer. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of 
the Centers for Disease Control and Prevention (CDC).
Potential conflicts of interest. All reported support was received outside of the submitted work. W. H. S. reports grants from 
BioMerieux, Affinium Pharmaceuticals, Astute Medical, BRAHMS GmbH/Thermo Fisher, Pfizer, Rapid Pathogen Screening, 
Venaxis, BioAegis Inc, Sphingotec GmbH, and Ferring Pharmaceuticals, and personal fees from BioFire Diagnostics, Venaxis, Abbott 
Point of Care, and Cempra Pharmaceuticals. E. J. A. reports personal fees from AbbVie, grants and nonfinancial support from 
MedImmune, and grants from Regeneron and Novavax. C. G. G. reports serving as a consultant for Pfizer. R. G. W. reports grants 
from the CDC, funds to conduct clinical research from BioMerieux and Vertex Pharmaceuticals, and personal fees from BioMerieux 
and Visterra Inc. D. J. W. reports grants from the CDC. K. M. E. reports serving on a data and safety monitoring board for Novartis for 
which her institution receives fees. W. H. S. reports grants from the CDC and personal fees from BioFire Diagnostics, Venaxis, Abbott 
Point of Care and Cempra Pharmaceuticals. All other authors report no potential conflicts. All authors have submitted the ICMJE 




J Infect Dis. Author manuscript; available in PMC 2017 December 11.
Published in final edited form as:





















Methods—Sera from RV-positive children and adults hospitalized with CAP were tested for RV 
by real-time reverse-transcription polymerase chain reaction. Rhinovirus species and type were 
determined by partial genome sequencing.
Results—Overall, 57 of 570 (10%) RV-positive patients were viremic, and all were children aged 
<10 years (n = 57/375; 15.2%). Although RV-A was the most common RV species detected from 
respiratory specimens (48.8%), almost all viremias were RV-C (98.2%). Viremic patients had 
fewer codetected pathogens and were more likely to have chest retractions, wheezing, and a 
history of underlying asthma/reactive airway disease than patients without viremia.
Conclusions—More than 1 out of 7 RV-infected children aged <10 years hospitalized with CAP 
were viremic. In contrast with other RV species, RV-C infections were highly associated with 
viremia and were usually the only respiratory pathogen identified, suggesting that RV-C viremia 
may be an important diagnostic indicator in pediatric pneumonia.
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Rhinoviruses (RVs), together with enteroviruses (EVs), are members of the Enterovirus 
genus, family Picornaviridae, and are further divided into 3 species (RV-A, -B, and -C) with 
>160 types [1]. Although RVs and EVs share a common genomic organization and both can 
cause acute respiratory disease, they exhibit significant differences in disease pathology. A 
hallmark of EV infections is their capacity for viremia and systemic infections [2], which 
has rarely been demonstrated for RVs using classical culture-based diagnostic methods [3, 
4]. However, recent studies using sensitive molecular methods have reported detection of RV 
in the blood of children presenting with respiratory illness [5–7].
Although more often associated with mild upper respiratory tract infections, RVs are now 
recognized as a major cause of exacerbations of asthma and other chronic pulmonary 
diseases [8, 9] and a cause of severe lower respiratory tract infections, including pneumonia 
[10–13]. In the Centers for Disease Control and Prevention (CDC) Etiology of Pneumonia in 
the Community (EPIC) study, RV was found to be the most commonly detected pathogen in 
the upper respiratory tract of patients hospitalized with community-acquired pneumonia 
(CAP) [12, 13]. However, RVs were also detected in a high proportion of asymptomatic 
pediatric controls [12, 14] and were often codetected with other respiratory pathogens [12], 
complicating determination of their causal relationship with CAP. Thus, the causality of RV 
in CAP is unknown but may correlate with viremia as defined by detection of RV RNA in 
the blood. Nested within the EPIC study, we determined the prevalence of RV viremia in 
RV-infected patients hospitalized with CAP and assessed correlations between viremia and 
corresponding virologic, demographic, and clinical features.
METHODS
Patient and Specimens
From 1 January 2010 to 30 June 2012, children and adults admitted to 8 hospitals located in 
Chicago, Memphis, Nashville, and Salt Lake City were enrolled in the EPIC study [12, 13]. 
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Enrollment criteria included evidence of CAP based on clinicians’ initial interpretation of 
chest radiographs obtained within 72 hours before or after hospital admission, and patients 
who were severely immunocompromised were excluded. Whereas previously published 
EPIC studies [12, 13] restricted incidence calculations to those patients whose chest 
radiographs were confirmed for evidence of pneumonia by independent board-certified 
radiologists, we included all enrolled RV-positive patients who had an acute serum specimen 
available. Study patients had acute serum and nasopharyngeal/oropharyngeal (NP/OP) 
swabs combined in viral transport media, with most (99.3%) collected within 72 hours of 
hospital admission; 42% of patients also had a convalescent serum specimen drawn 3–10 
weeks later. Serum was separated from clotted blood, aliquoted, and stored frozen at −70°C 
or colder prior to testing. Written informed consent was obtained from all patients or their 
caregivers before enrollment. The study protocol was approved by the institutional review 
board at each participating institution and the CDC.
Rhinovirus Real-Time Reverse-Transcription Polymerase Chain
Reaction Assay—Patients had previously been tested for multiple respiratory viral, 
bacterial, and fungal pathogens by molecular methods, serology, and culture at the study 
sites and CDC [12, 13]. For this study, we tested NP/OP specimens and corresponding acute 
serum specimens from RV-positive patients. Total nucleic acids were extracted from both 
serum and NP/OP specimens (200 μL) on a NucliSens EasyMAG (BioMerieux). The 
extracts were tested by a real-time reverse transcription-polymerase chain reaction (rRT-
PCR) assay [15] with a modified forward primer (5′-CYALNAGCCTLNAGCGTGGY-3′) to 
expand RV-C type coverage and using the AgPath-ID One-Step RT-PCR Kit (Thermo Fisher 
Scientific). Cycle threshold (Ct) values <40 Ct were considered positive and were used as a 
proxy for virus load. The NP/OP and serum specimen extractions and rRT-PCR were 
performed on separate days to minimize potential for cross-contamination.
Rhinovirus Molecular Typing—Molecular typing of RVs detected from NP/OP 
specimens of patients enrolled at the 3 children’s hospitals was initially performed by the 
University of Utah Health Sciences Center (method available on request); RV genotypes 
were subsequently confirmed by the CDC for children with viremia. For adult patients, RV 
typing from NP/OP and serum specimens was performed at the CDC. Rhinovirus typing was 
based on RT-PCR and sequencing of the VP4/VP2 capsid gene region spanning nucleotide 
positions 626–1046 (numbering according to reference strain RV-A1, GenBank accession 
no. FJ445111.1). In brief, 5 μL of total nucleic acid extract was subjected to RT-PCR 
amplification with SuperScript III One-Step RT-PCR System with Platinum Taq DNA 
Polymerase (Thermo Fisher Scientific) in a final volume of 25 μL following manufacture’s 
protocol using external forward primer (5′-GGCCCCTGAATGYGGCTAA-3′) and reverse 
primer (5′-GCATCIGGYARYTTCCACCACCANCC-3′). The RT-PCR cycling conditions 
were 55°C for 30 minutes and 94°C for 2 minutes followed by 40 cycles of 94°C for 30 
seconds, 52°C for 30 seconds, and 68°C for 50 seconds, with a final extension of 68°C for 5 
minutes. One μL of the RT-PCR product was then added to a seminested reaction using 
internal forward primer (5′-ACTACTTTGGGTGTCCGTGTTTC-3′) and reverse primer in 
a final volume of 50 μL using Taq DNA Polymerase (Roche Applied Science). The PCR 
cycling conditions were 95°C for 2 minutes followed by 30 cycles of 95°C for 30 seconds, 
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55°C for 30 seconds, and 72°C for 40 seconds, with a final extension of 72°C for 5 minutes. 
Seminested amplicons were resolved on 1% agarose gels and purified using ExoSAP-IT 
(USB Corporation). Amplicon sequencing was performed in both directions using BigDye 
Terminator v1.1 Cycle Sequencing Kit on a 3730XL Genetic Analyzer (Thermo Fisher 
Scientific) using internal forward and reverse primers. Sequencher version 5.3 software 
(Gene Codes) was used for sequence assembly and editing. VP4/VP2 nucleotide sequences 
were aligned using Clustal X version 1.83 as implemented in BioEdit version 7.2.5. (Ibis 
Biosciences), and phylogenetic trees were constructed by the neighbor joining method using 
a maximum composite likelihood substitution model with pairwise deletion of gaps and 
missing data as implemented in MEGA7: Molecular Evolutionary Genetics Analysis version 
7.0 [16]. Rhinovirus species and provisional genotype assignments were based on 
phylogenetic congruence of VP4/VP2 sequences and pairwise nucleotide divergence criteria 
developed by McIntyre et al [1]. Sequences generated in this study were deposited in 
GenBank under the accession numbers MF579447–MF579503.
Statistical Analysis
Statistical analyses were performed using SAS version 9.3 (SAS Institute). Chi-square and 
Wilcoxon rank-sum tests were performed to assess clinical and demographic associations of 
children with and without RV viremia. The Mann–Whitney U test was used for pair-wise 
comparison of Ct values as a proxy for viral loads in respiratory specimens among RV 
species. A P value < .05 was considered statistically significant.
RESULTS
Study Population
Of 2638 children enrolled in the EPIC study, 723 (27.4%) had RV detected in their NP/OP 
specimens, among whom 416 (57.5%) had acute serum available; of these, 356 (85.6%) had 
radiographically confirmed pneumonia. Of 2488 enrolled adults, 209 (8.4%) had RV 
detected in their NP/OP specimens, among whom 154 (73.7%) had acute serum available; of 
these, 146 (94.8%) had radiographically confirmed pneumonia.
Rhinovirus NP/OP and Viremia-Associated Species/Genotypes
Of the 570 RV-NP/OP–positive patients from whom serum was available, RVs were all 
successfully typed from the NP/OP specimens. Rhinovirus A was identified in 278 (48.8%), 
RV-B in 39 (6.8%), and RV-C in 253 (44.4%) (Table 1). Rhinovirus viremia was detected by 
rRT-PCR in the acute serum of 57 (10%) of these patients. Overall, 56 of 57 (98.2%) 
viremias were associated with RV-C, and the remaining 1 viremia was associated with RV-
A. Identical VP4/V2 sequences were obtained from both the respiratory and acute serum 
specimens of all viremic patients except for one 6-month-old child with RV-A identified in 
the respiratory specimen and RV-C in the serum. Convalescent sera collected a median of 27 
days (range, 14–51 days) after the acute specimen from 29 viremic patients were all rRT-
PCR negative for RV. Phylogenetic analysis of the RV-C VP4/VP2 sequences identified >25 
different genotypes (Figure 1). In addition, a cluster of closely related RV-C sequences 
obtained from 4 patients enrolled at EPIC study sites in 3 different states diverged by >23% 
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from other known RV-C genotypes, which exceeded the 10% threshold for new genotype 
assignment in the VP4/VP2 region [1] and therefore may represent a new genotype.
Rhinovirus NP/OP and Age Group
Most RV detections from NP/OP specimens (65.8%) were in children aged <10 years, and 
proportionately more detections of RV-C (n/N = 211/253; 83.4%) were in this age group 
than detections of RV-A (n/N = 146/278; 52.5%; P < .0001) or RV-B (n/N = 18/39; 46.2%; P 
< .0001) (Table 1).
Compared with RV-C (median age, 3.0 y; interquartile range [IQR], 1–6 y), other RV species 
were more commonly detected in older patients (RV-A: median age, 8.0 y; IQR, 1–50 y, P 
< .0001; RV-B: median age, 16.0 y; IQR, 4–54 y, P < .0001).
Rhinovirus Viremia and Age Group
Rhinovirus viremia varied significantly with age (P < .0001) (Table 1). Overall, RV viremia 
was detected in 15.2% of 375 patients aged <10 years with RV detected from NP/OP 
specimens. The proportion of patients with viremia increased with age from 3.9% in 
children aged <6 months to a peak of 26.3% in children aged 12–23 months. Rhinovirus 
viremia then declined and was not detected in patients aged ≥10 years.
Rhinovirus Viremia and NP/OP Respiratory Viral Load
We compared median Ct values from NP/OP specimens for each RV species to determine 
whether virus load in the upper respiratory tract might account for differences among RV 
species associated with viremia (Figure 2). Median NP/OP Ct values for RV-A (median Ct, 
26.4; IQR, 23.5–29.7) and RV-C (median Ct, 26.5; IQR, 23.3–29.0) did not differ 
significantly from each other but were significantly lower for both RV-A and RV-C 
(representing higher virus loads) than for RV-B (median Ct, 28.4; IQR, 25.5–31.8). Among 
patients with RV-C, median Ct values were significantly lower among those with a 
detectable viremia (median Ct, 24.8; IQR, 22.1–28.1) than those without viremia (median 
Ct, 26.6; IQR, 23.8–29.4).
Rhinovirus Viremia and Codetection With Other Respiratory Pathogens
We compared proportions of codetections in patients with and without RV viremia to 
determine whether patients with viremia were less likely to be coinfected with another 
respiratory pathogen that could account for the illness. Among 566 (99.3%) patients with 
RV-positive respiratory specimens and available test results for bacterial and other viral 
pathogens, 143 (25.3%) had another viral or bacterial respiratory pathogen infection 
detected. Among 372 patients aged <10 years with RV detected from the respiratory 
specimen and available test results for other pathogens, 7 of 57 (12.3%) with RV viremia 
also had another pathogen detected compared with 107 of 315 (34.0%) without viremia (P 
= .001). Interestingly, all codetections were viruses, including respiratory syncytial virus (n 
= 3), influenza virus (n = 2), parainfluenza virus (n = 1), and respiratory syncytial virus/
adenovirus (n = 1).
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Rhinovirus Viremia and Clinical Features
We compared the clinical features of 375 patients aged <10 years with RV-positive NP/OP 
specimens with and without RV viremia. Patients with viremia were significantly more 
likely to have chest retractions (61.4% vs 45.9%; P < .05) or wheezing (86.0% vs 61.3%; P 
< .001) at enrollment and to have preexisting asthma/reactive airway disease (59.7% vs 
41.2%; P < .05) than those without viremia. There were no differences in intensive care 
admission, mechanical ventilation, deaths, length of hospital stay, or chest radiographic 
features within 48 hours of admission between RV viremic and nonviremic children.
DISCUSSION
In this large, multisite study of CAP, we detected RV viremia in 10% of 570 hospitalized 
patients with RV detected from upper respiratory tract specimens. Our findings were similar 
to several international reports of RV viremia detected by RT-PCR in children with acute 
respiratory RV infections [5–7]. A study from Greece detected RV viremia in 10 of 88 
(11.4%) children presenting with acute respiratory symptoms ranging from common colds to 
pneumonia [5]; a study from Italy detected RV viremia in 6 of 50 (12.0%) children with 
fever and acute respiratory symptoms [6]; and a study from Japan detected RV viremia in 30 
of 243 (12.3%) children hospitalized in the Philippines with severe lower respiratory tract 
infections [7]. Although these studies examined RV respiratory tract infections of varied 
clinical severity among mostly young children, our study was larger, included all age groups, 
and focused on hospitalized patients diagnosed with CAP, of which nearly 90% of 
pneumonias were subsequently confirmed on radiographic review.
Before the advent of sensitive molecular diagnostic tests, RV infections were thought to 
remain localized to the mucosal epithelium of the upper respiratory tract [17]. Using culture-
based detection methods, RV viremia had only been reported from a few children with 
sudden and unexpected death [3, 4]. Past failures to culture RV from blood might be 
explained by the predominance of RV-C in viremia (see below), which is known to not grow 
well in conventional cell lines [18]. With some recent exceptions [19, 20], acute RV 
infections have rarely been associated with disseminated disease, unlike EVs, where viremia 
can lead to infection of multiple sites with varied clinical manifestations [21]. However, 
blood detection of RV by RT-PCR may only represent identification of RV RNA and not true 
viremia with viable virus.
Routes of RV entry into the bloodstream are unknown. Experimental studies have shown 
that RV can infect lower respiratory tract airways [22, 23], and individual case reports have 
documented RV infection of the lung [24, 25]. Direct infection and viral-mediated injury of 
the lung might hypothetically lead to direct viral seeding of the blood. However, RV viremia 
has also been found in children presenting with only upper respiratory tract symptoms [4, 6], 
suggesting that infection of the lower respiratory tract may not be required for bloodstream 
access. Rhinovirus RNA and infected cells have been found in tonsils and adenoid tissues 
that facilitate antigen capture and immune cell recruitment [26, 27]. These tissues are 
drained by efferent lymphatic vessels that may serve to convey RV to the bloodstream.
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Although there were more RV-A detections from respiratory specimens of study patients 
than RV-C detections, RV-C accounted for almost all viremias (98.2%). Differences in virus 
load in the upper respiratory tract did not appear to explain this finding; median Ct values 
were similar for RV-A and RV-C, although lower median Ct values (representing higher 
virus loads) for RV-C were associated with viremia. Our findings are consistent with other 
studies that compared proportions of viremias among children with acute RV respiratory 
tract infections by virus species [6, 7]. Of the 6 children with RV viremia detected by 
Esposito et al [6], 4 (66.7%) were identified as having RV-C. Of the 30 children with RV 
viremia detected by Fuji et al [7], 26 (86.7%) were found to have RV-C; interestingly, these 
authors found that the 4 patients with RV-A viremia all possessed RV-C-like 5′non-coding 
regions (NCRs) acquired through recombination, leading the authors to speculate that the 
RV-C 5′NCR might mediate viremia. However, the 5′NCR of the RV-A that we identified 
from a single viremic patient did not show evidence of recombination in this region (data not 
shown). Like Fuji et al [7], we found a wide range of RV-C genotypes without obvious 
phylogenetic clustering, suggesting that viremia is not genotype-specific.
We found young age to be strongly associated with RV viremia. Rhinovirus viremia peaked 
in children aged 1–2 years, with lower prevalence in infants aged <6 months and declining 
prevalence with increasing age after 2 years; viremia was not detected among patients aged 
≥10 years. Clearance of RV from blood by maternal antibodies may explain the lower 
prevalence in infants aged <6 months [7, 28]. Because RV infections peak in early childhood 
[29], with reinfections occurring with increasing age, immune memory and cross-protective 
RV immunity may lead to more rapid virus clearance from blood and explain the subsequent 
decline in viremia. A further contributing factor may be that RV-C infections were 
proportionately more common in young children as compared with other RV species and 
more commonly associated with viremia [6, 7].
Multiple epidemiologic studies that compared RV species found RV-C to be more frequently 
associated with severe respiratory infections, particularly in children with asthma [8, 9, 30–
32]. Although we found no clear differences in severity of RV infections between patients 
with and without viremia, patients with viremia were more likely to have chest retractions or 
wheezing symptoms at enrollment and were more likely to have preexisting asthma/reactive 
airway disease. In those studies of RV viremia in children hospitalized with severe 
respiratory illnesses, viremia was more often associated with increased severity measures 
suggestive of lower respiratory infection, including decreased oxygen saturation levels [6, 7] 
and required oxygen therapy [6]. Personal history of asthma and proportion of asthma 
exacerbations were significantly associated with RV viremia [5], as was wheezing [7]. 
Together, these findings suggest that the pathophysiology of infection with RV-C may differ 
from other RV species. A unique feature of RV-C is its use of the cadherin-related family 
member 3 (CDHR3) protein for host cell entry [33], whereas RV-A and RV-B use 
intercellular adhesion molecule 1 or low-density lipoprotein receptor family members. 
Interestingly, CDHR3 has been identified as a susceptibility locus for early childhood 
asthma [34]. Moreover, cells expressing genetic variants of CDHR3 show enhanced binding 
efficiency for RV-C and increased virus production, suggesting that these variants could be a 
risk factor for RV-C–associated childhood wheezing and asthma hospitalization [33, 35]. 
Further studies will be needed to determine the relationship between receptor utilization and 
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pathophysiology of RV-C infection and whether viremia might be an indicator of or 
contributor to this process.
Rhinovirus infections in young children are often subclinical or are codetected with other 
respiratory pathogens, complicating disease attribution [36]. In the original EPIC study [12], 
>42% of all RV-positive pediatric patients had another respiratory pathogen detected, which 
could account for patient illness. Some studies that compared RV species in persons with 
acute respiratory infections have found codetection prevalence to be significantly lower in 
those with RV-C [10, 31]. We found significantly fewer codetections among RV-C infected 
patients with RV viremia, suggesting that viremic RV-C infections may be more indicative of 
pediatric pneumonia than nonviremic episodes.
Our study had several limitations. First, not all RV-positive patients had acute serum 
specimens available for testing, and specimen collection times from onset of patient reported 
symptoms varied and may have been suboptimal in some patients for viremia detection. We 
were restricted to specimens collected from the upper respiratory tract, preventing 
assessment of possible correlation of RV viremia with lower respiratory tract viral loads. 
Others have shown that sample collection timing and sample type (serum vs whole blood) 
might impact the ability to detect virus [5, 7]. Finally, because this study was restricted to 
patients hospitalized with more severe respiratory illness, further studies of RV viremia that 
include healthy controls and cases with milder respiratory symptoms are needed.
In conclusion, we detected RV viremia in hospitalized CAP patients aged <10 years with 
RV-positive upper respiratory tract specimens. Compared with other RV species, RV-C was 
almost exclusively associated with viremia and was more often the only respiratory 
pathogen identified in viremic patients. Although causality cannot be conclusively inferred, 
these findings strongly suggest that RV-C is an important cause of pediatric pneumonia and 
that viremia may be a useful diagnostic indicator.
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Neighbor-joining tree of rhinovirus (RV) VP4/VP2 nucleotide sequences from 57 viremic 
patients (open and solid circles); numbers are genotype designations of RV-A, -B, and -C 
reference strain sequences available from GenBank. Solid circle denotes patient with RV-C 
detected in the acute serum and RV-A detected in the respiratory specimen. Box highlights 4 
similar sequences obtained from different patients that show >23% divergence from known 
RVs and may represent a new virus genotype. Scale bar shows genetic distance as nucleotide 
substitutions per site. Boostrap values (1000 replicates) are indicated at the RV species 
nodes.
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Box-and-whisker plots of rhinovirus (RV) real-time reverse-transcription polymerase chain 
reaction cycle threshold (Ct) values obtained from respiratory specimens from patients with 
RV-A, RV-B, and RV-C infections and comparing patients with RV-C with and without RV 
viremia. Note that of 56 patients with RV-C viremias, only 55 had corresponding RV-C 
detections from respiratory specimens (*). Whiskers mark the lowest and highest Ct values; 
boxes are bounded by the 25th and 75th percentiles; and box bisecting lines represent 
median Ct values. Sample size is indicated for each category. Differences (Δ) in median Ct 
values for each category are given as well as P values calculated by the Mann-Whitney U 
test. Abbreviations: Ct, cycle threshold; NP/OP, nasopharyngeal/oropharyngeal; NS, not 
significant, rRT-PCR, real-time reverse-transcription polymerase chain reaction; RV, 
rhinovirus.
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Table 1
Rhinovirus Detections in Acute-Phase Serum (n) and Corresponding Nasopharyngeal/Oropharyngeal 





n/N (%)n/N (%) n/N (%) n/N (%)
<6 mo 0/27 (0.0) 0/4 (0.0) 2/20 (10.0) 2/51 (3.9)
6–11 mo 0/25 (0.0) 0/2 (0.0) 5/28 (17.9)a 5/55 (9.1)
12–23 mo 1/25 (4.0) 0/3 (0.0) 20/52 (38.5) 21/80 (26.3)
24–59 mo 0/38 (0.0) 0/2 (0.0) 20/58 (34.5) 20/98 (20.4)
5–9 y 0/31 (0.0) 0/7 (0.0) 9/53 (17.0) 9/91 (9.9)
10–17 y 0/28 (0.0) 0/2 (0.0) 0/11 (0.0) 0/41 (0.0)
≥18 y 0/104 (0.0) 0/19 (0.0) 0/31 (0.0) 0/154 (0.0)
Total 1/278 (0.4) 0/39 (0.0) 56/253 (22.1) 57/570 (10.0)
Abbreviations: RV, rhinovirus.
a
RV-C detected in the serum of 1 patient, and RV-A detected in the corresponding respiratory specimen.
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Table 2
Comparison of Clinical Characteristics of 375 Hospitalized Community-Acquired Pneumonia Patients Aged 
<10 Years With and Without Rhinovirus Viremia
Characteristic
RV viremia
Positive, no. (%) Negative, no. (%) P value
Total 57 (15.2) 318 (84.8)
Female sex 28 (49.1) 139 (43.7) NS
Age, y, median (IQR) 2.0 (1–4) 2.0 (0–5) NS
Symptoms at presentation
 Cough 52 (91.2) 292 (91.8) NS
 Wheezing 49 (86.0) 195 (61.3) <.05
 Shortness of breath 47 (82.5) 222 (69.8) NS
 Fever/feverish 42 (73.7) 256 (80.5) NS
 Rhinorrhea 42 (73.7) 234 (73.6) NS
 Anorexia 38 (66.7) 224 (70.4) NS
 Chest retractions 35 (61.4) 146 (45.9) <.05
Patient interview
 Respiratory illness in the past month 16 (28.1) 80 (25.2) NS
 Ever diagnosed with pneumonia 16 (28.1) 69 (21.7) NS
 Antibiotics prior to hospitalization 7 (12.3) 58 (18.2) NS
 Supplemental oxygen at home 3 (5.3) 12 (3.8) NS
 Influenza antivirals prior to hospitalization 0 (0.0) 4 (1.3) NS
Social history
 Lives in household with indoor or outdoor smoking 23 (40.4) 119 (37.4) NS
 Household member with respiratory illness in past month 21 (36.8) 107 (33.7) NS
 Attend daycare (among persons aged <6 y) 14/50 (28.0) 72/260 (27.7) NS
Medical conditions
 Any 1 condition 42 (73.7) 174 (54.7) <.05
 Asthma/reactive airway disease 34 (59.7) 131 (41.2) <.05
 Congenital heart disease 6 (10.5) 17 (5.4) NS
 Neurologic disorder 6 (10.5) 17 (5.4) NS
 Preterm birth among persons aged <2 y 7/28 (25) 30/158 (19) NS
Hospitalization
 Intensive care unit admission 13 (22.8) 70 (22.0) NS
 Mechanical ventilation 4 (7.0) 21 (6.6) NS
 Death 0 (0.0) 1 (0.3) NS
 Hospital stay, d, median (IQR) 2/1–3 2/1–4 NS
Chest radiograph features (within 48 h of admission)a
 Alveolar and/or interstitial infiltrate 28 (50.0) 156 (52.7) NS
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Characteristic
RV viremia
Positive, no. (%) Negative, no. (%) P value
 Consolidation 26 (46.4) 138 (46.6) NS
 Complicated bronchiolitis 22 (39.3) 114 (38.5) NS
 Pleural effusion 0 (0.0) 28 (9.5) NS
Abbreviations; IQR, interquartile range; NS, not significant; RV, rhinovirus.
aAmong patients with an abnormal initial chest radiograph
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